MOLECULAR STUDY OF Acinetobacter baumannii USING 16S RRNA AND 
BLA OXA-51 GENE ISOLATED FROM HOSPITALS IN DUHOK-
KURDISTAN REGION, IRAQ

MARWAN KHALIL QADER
Dept. Biology, College of Science, University of Duhok, Kurdistan Region-Iraq

(Received: September 16, 2020; Accepted for Publication: February 28, 2021)

ABSTRACT
Background and objective: Acinetobacter baumannii is pathogenic and multiresistant bacteria that cause nosocomial infection. The aim of this study are diagnosis A. baumannii by using specific bla OXA-51 and 16SrRNA.

Methods: out of 150 Acinetobacter species samples were collected from patients in Azadi teaching hospital, Duhok Emergency hospital; and burn Duhok cosmetic and burn hospital from May 2020 to August 2020. The samples were phenotypically diagnosed by bacteriological strategy. Out of 100 samples were selected and by molecular level confirmed as Acinetobacter spp.

Results: isolates were revealed as small, pale, and late-lactose fermenter colonies on MacConkey agar appeared as a creamy, opaque, andnon-hemolytic colony on blood agar All suspected isolates, as A. baumannii, were growing at 44°C. By using the genus-specific bla OXA-51 primer that produced 353 bp amplification band and 75 samples were diagnosed by PCR as A. baumannii by 16S rRNA as a specific primer and showed 150 bp amplicon. 10 samples out of the 75 resembling A. baumannii were identified as a multidrug resistant isolates by method of diffusion. Disc. A. baumannii isolates displayed a high resistance rate of 85% to azithromycin and 80% to imipenem. Moreover, amikacin, meropenem, and gentamycin, Trimethoprim-Sulfamethoxazole, and ciprofloxacin, norfloxac in showed a low level of efficacy against A. baumannii isolates with the resistant rate of 88%, 90%, 90%, and 93% respectively.

KEYWORD: Acinetobacter baumannii, bla OXA-51, multi-drug resistant, 16S rRNA, PCR

1. INTRODUCTION

Acinetobacter is currently classified under the family Moraxellaceae, which includes the genera Moraxella, Psychrobacter, and other related organisms (Almasaudi., 2018). Acinetobacter baumannii (A. baumannii) is considered as an opportunistic pathogen causing nosocomial infections in hospitalized patients, particularly in Intensive care units (ICU), as well as community-acquired infections (Jessie et al., 2020). These infections include pneumonia, bloodstream infection, skin and soft tissue infections, wound infection, meningitis, urinary tract infection and endocarditis (Liu et al., 2017). Acinetobacter infections have been historically associated with military and injured soldiers in combat due to direct environmental contamination of wounds (Diancourt et al., 2010). During the past decade, the incidence of nosocomial outbreaks by A. baumannii has been described mostly in burn, surgical and intensive care units (Jafari and Karbasizade, 2014). Most surveillance studies report high mortality rates among patients with A. baumannii bacteremia and may be associated with considerable morbidity and mortality reach up to 70% (Wong et al., 2017). The management and prevention of A. baumannii spreading health care settings require identifying potential reservoirs of this organism, the modes of transmission and investigating A. baumannii clones which cause the outbreaks from epidemiologically unrelated strains. A comparison of isolates at the subspecies level is required by the application of molecular typing methods (Sadeghi et al., 2016). The use of molecular tools, especially the Polymerase Chain Reaction (PCR), has a great impact on simplifying and specificity for identification, characterization, and taxonomy of infectious agents (Shahi et al., 2018).

2- MATERIALS AND METHODS

Out of 150 samples were collected from burns and sputum inpatients in Azadi teaching hospital, Duhok Emergency hospital; and burn Duhok cosmetic and burn hospital between
May-August 2020 both genders bunches. The tests were managed according to the standard bacteriological strategy including: growth on MacConkey agar, blood agar, catalase and oxidase tests, (McFaddin, 2000). All clinical samples were undergoing to DNA extraction tests by using the genomic DNA purification kits (Bioneer®, Korea); DNA results was showed by light of UV and then electrophoresed on agarose gel. 1 % (Ghaima et al., 2016). PCR was done by adding 4 ml of the genomic of bacteria to 12.5 ml mastermix (Merk KgaA PCR premix(Germany)), and also add 1.2 ml (20 picomolμl) of the bla OXA-51 primer (Ghaima et al., 2016). the final volume was completed by adding 6.1 ml Dionized distilled water. The amplification sizes groups and primers sequences of bla OXA-51 and 16 rRNA show in table 1 PCR conditions for increasing bla OXA-51 quality is outlined in table2.

| Gene          | Forward primer                  | Reverse primer                  | Product size(bp) |
|---------------|--------------------------------|---------------------------------|------------------|
| OXA-51        | 5- TAATGCTTTGATCGGCTTG-3        | 5- TGGATTGCACCTCACTTT GG-3     | 353              |
| 16 rRNA       | 5- CAGCTC GTGTCGAGATGT-3        | 5'- CGTAAGGGCCATGATGACTT-3     | 150              |

16 sRNA primers in table 3, the running conditions for the amplification of 16 sRNA of A. baumannii gene showed in table 3, PCR product tests were run on gel electrophoresis on 1 % agarose and the DNA bands were showed under light of UV and shot by Camera (Ghaima et al., 2016). Anti-microbial sensitivity profile test of A. baumannii samples continued by the method of Diffusion Disc strategy on Mueller-Hinton agar, and a group of antimicrobs was chosen according type of Bacteria. Strategy entirely used by (Ghasemi et al., 2018).

| Gene          | Forward primer                  | Reverse primer                  | Product size(bp) |
|---------------|--------------------------------|---------------------------------|------------------|
| OXA-51        | 5- TAATGCTTTGATCGGCTTG-3        | 5- TGGATTGCACCTCACTTT GG-3     | 353              |
| 16 rRNA       | 5- CAGCTC GTGTCGAGATGT-3        | 5'- CGTAAGGGCCATGATGACTT-3     | 150              |

16 sRNA primers in table 3, the running conditions for the amplification of 16 sRNA of A. baumannii gene showed in table 3, PCR product tests were run on gel electrophoresis on 1 % agarose and the DNA bands were showed under light of UV and shot by Camera (Ghaima et al., 2016). Anti-microbial sensitivity profile test of A. baumannii samples continued by the method of Diffusion Disc strategy on Mueller-Hinton agar, and a group of antimicrobs was chosen according type of Bacteria. Strategy entirely used by (Ghasemi et al., 2018).

RESULTS

all the enlisted 150 clinical sample were showed phenotypic characteristics of Acinetobacter spp. isolates were revealed as small, pale, and late-lactose fermenter colonies on MacConkey agar appeared as a creamy, opaque, and non-hemolytic colony on blood agar. All suspected isolates, as A. baumannii, were growing at 44ºC, which indicates the ability of these bacteria to grow at the high-temperature degree (Belay et al., 2018). The samples disclosed the presence of genomic of bacterial DNA after extraction method. Results moreover affirmed that arbitrarily chosen 100 samples had been distinguished as Acinetobacter spp at the molecular level. (Figure 1)
For the molecular recognizable proof of *A. baumannii*, primer was utilized to distinguish target 16 S rRNA, and the result appears that 75 out of the arbitrarily chosen 100 samples in 150 bp species-specific amplicon Figure 2. The results of the antibiotic sensitivity test by the Kirby Bauer method are shown in Table 4. Colistin was considered as one of the most powerful antimicrobial agents, where none of these isolates were resistant to this antibiotic. Doxycycline with a resistance rate of 39% may be considered as the second most effective antimicrobial against *A. baumannii* isolates. Similarly, levofloxacin had a moderate effect on *A. baumannii* isolates with a 51% resistant rate. Indeed, *A. baumannii* isolates displayed a high resistance rate of 85% to azithromycin and 80% to imipenem. Moreover, amikacin, meropenem, and gentamycin, Trimethoprim-Sulfamethoxazole, and ciprofloxacin, norfloxacin showed a low level of efficacy against *A. baumannii* isolates with the resistant rate of 88%, 90%, 90%, and 93% respectively. Our results revealed that 10 *A. baumannii* isolates (24.4%) were found to be multidrug-resistant (MDR) and 27 isolates (65.9%) were XDR. Determination of MDR and XDR among isolates of *A. baumannii* was done according (Coskun et al., 2019) who define MDR as a resistance to at least one agent in three or more classes of antimicrobial agents, while XDR is resistance to at least one agent in all classes but remained sensitive to only one or two antimicrobial agents (Coskun et al., 2019).

### Table 4: Antibiotic resistance profile

| Antibiotics                   | Code | Sensitivity | Resistance |
|-------------------------------|------|-------------|------------|
| Amikacin                      | AK   | 5           | 36         | 88%        |
| Gentamycin                    | CN   | 4           | 37         | 90%        |
| Ciprofloxacin                 | CIP  | 2           | 39         | 95%        |
| Levofloxacin                  | LEV  | 18          | 23         | 56%        |
| Norfloxacin                   | NOR  | 1           | 40         | 90%        |
| Doxycyclin                    | DO   | 23          | 18         | 44%        |
| Trimethoprim-Sulfamethoxazole | SXT  | 3           | 38         | 93%        |
| Azithromycin                  | AZM  | 6           | 35         | 85%        |
| Imipenem                      | IPM  | 8           | 33         | 80%        |
| Meropenem                     | MEM  | 4           | 37         | 90%        |
| Colistin                      | CT   | 41          | 0          | 0%         |

Marwan.qader@uod.ac
**DISCUSSION**

*A. baumannii* strains is increasing, particularly affecting patients who are immunocompromised and hospitalized in intensive care and burns units (Sepideh et al., 2020). *A. baumannii* could be a significantly advanced nosocomial microorganism that’s regularly experienced in clinic settings in portion due to the capacity of this bacterium to survive on dry or moist surfaces, on healthy skin and may be present in foodstuffs, in addition to its ability, to recruit different intrinsic and acquired mechanisms to resist different antibiotics (Abbott et al., 2013). *A. baumannii* moreover improvements of its chromosomal DNA which allow phenotypic transformation and in this way increment the potential for creating antimicrobial resistance and the capability to outlive in seagoing conditions on restricted supplements supply (Zarrilli et al., 2009). An OXA-51-like gene is the largest group which belongs to the Ambler Class D oxacillinase group (OXA-type). There are 95 enzymes variants of this group that have been identified to date (Evans and Amyes, 2014). These enzymes are intrinsic and naturally exist in the chromosomal DNA of *A. baumannii* inherited into all strains (Shahi et al., 2018). This fact makes it a wonderful marker successfully applied for the detection of *A. baumannii* at the species level (Shahi et al., 2018; Ghaima et al., 2016). Although all these enzymes play an important role in resistance against carbapenems, only two of the OXA-51-like enzymes, including; OXA-51 and OXA-69 showed weak hydrolytic activity toward the carbapenems (Zarrilli et al., 2009). Therefore, the OXA-51 gene presents among all *A. baumannii* strains. It is worth to mention that the insertion of the IS element *A. baumannii* 1 (ISAba1) upstream of the OXA-51 gene may change the expression of this gene which results in resistance to board spectrum antibiotics (Esther et al., 2013). 16S rRNA gene used as a marker for the identification of different bacteria at the genus level because it is more powerful, reproducible and precise than those results obtained via conventional methods (Belay et al., 2018). using 16S rRNA sequences, it is possible to study bacterial taxonomy and phylogeny. So far, it is the most common genetic marker used for a number of reasons. It is present in almost all bacteria, often presenting in operons or multigene family and has consensus sequence with the function of the 16S rRNA region which has not changed over the time (Susanna et al., 2015).

According to the antibiotic sensitivity profile, the high risk of these isolates has been identified due to exposing a high resistance rate against most of the used antibiotics. The results of antibiotics in this study are recorded according to CLSI guidelines (Clinical and Laboratory Standards Institute, 2016). Colistin considered antimicrobial agent that has an effect on all isolates with a 100% sensitivity rate (Table 4). This result was agreed with results reported in Turkey by (Coskun et al., 2019) who found none of *A. baumannii* isolates were resistant to colistin. Notwithstanding, different researches have been recorded the emergence of *A. baumannii* strains that developed resistance against colistin during treatment and subsequently responsible for disastrous outbreaks (Diancourt et al., 2010). The emergence of *A. baumannii* isolates is resistant to colistin which has been reported in other studies conducted in Baghdad hospitals by (Ghaima et al., 2016) who recorded these isolates in resistant rate 37.5%. Colistin is a polypeptide antibiotic exposed high effectiveness against carbapenem-resistant Gram-negative bacteria which was usually
intravenously administrated with high dose (Bergen et al., 2012). Doxycyclin considered as the second most active antimicrobial agent with a resistance rate of 44%. Somehow, this result agreed with the obtained results by (Hussein et al., 2013) who recorded 45%. However, the wide dissemination of ribosomal protection proteins and efflux pumps in A. baumannii protect it from these antibiotics and limit their therapeutic use (Doi et al., 2015). Regarding their resistance to quinolones (levofloxacin and norfloxacin) showed with varied rates ranged from 56% to 98%, respectively. Levofloxacin was the most effective antibiotic among the quinolones group. It had a moderate effect on A. baumannii isolates. On the other hand, ciprofloxacin and norfloxacin were low effective against these isolates. This results were agreed with (Balaky et al., 2019) in Western Emergency Hospital Erbil, who showed that these isolates exhibited a high resistant rate (95% and 61%) to ciprofloxacin and levofloxacin, respectively. These isolates showed highly none susceptibility to Trimethoprim–Sulfamethazoxide with the rate of 93%. This antibiotic is a synergistic effect through a combination of TMP–SMX drugs to inhibit bacterial DNA synthesis (Karageorgopoulos and Falagas, 2008). Regarding the ability of the isolates to resistant to aminoglycosides (amikacin, gentamicin) and (azithromycin), they exhibited a high resistant rates which were 88%, 90%, and 85%, respectively, and it were agree with another results recorded A. baumannii strains with a high resistant rate (69.6% and 88.7%) to Amikacin and Gentamycin respectively (Shah et al., 2012). It’s worthy to mention that gentamycin and amikacin are the most recommended options for the treatment of infections caused by A. baumannii (Clinical and Laboratory Standards Institute, 2016). Generally, it has been found that tobramycin and amikacin exhibited a more potent effect than to gentamycin (Fishbain and Peleg, 2010). The usage of aminoglycosides in an intravenous administration as well as aerosol form approved high effectiveness for patients with cystic fibrosis and shows potential results among VAP patients (Badawy et al., 2020). The results of this study also showed a high resistant pattern to Meropenem and Imipenem with a resistance rate of 90% and 80% respectively. In many years, the carbapenems were considered as the last instance for treatments of different infectious diseases (Abbott et al., 2013). However, the resistance of A. baumannii to expanded-spectrum cephalosporins and carbapenems is rapidly growing over the years and limits therapeutic options, relying on polymyxins in combinations with other antibiotics (Chang et al., 2015). The survival and existence of MDR A. baumannii in environmental hospitals may be the main cause of nosocomial infections worldwide (Ghasemi et al., 2018). Many researches in other countries including Iran and Turkey, have recorded a high percentage of MDR as well as XDR among A. baumannii strains (Heidari et al., 2018). The emergence of MDR A. baumannii strains largely associated with high mortality among hospitalized patients (Kanafani et al., 2013). Furthermore, the emergence of XDR A baumannii strains may alarm the complication of treatment due to the ability of these isolates to resistant to almost all antibiotics but colistin.

REFERENCES

Almasaudi S. B. (2018). Acinetobacter spp. as nosocomial pathogens: Epidemiology and resistance features. Saudi journal of biological sciences, 25(3), 586–596. https://doi.org/10.1016/j.sjbs.2016.02.009

Jessie L Allen, Brooke R Tomlinson, Leila G Casella, Lindsey N Shaw (2020). Regulatory networks important for survival of Acinetobacter baumannii within the host, Current Opinion in Microbiology, 55:74-80

Liu, Y. M., Lee, Y. T., Kuo, S. C., Chen, T. L., Liu, C. P., and Liu, C. E. (2017). Comparison between bacteremia caused by Acinetobacter pittii and Acinetobacter nosocomialis. J. of Microbiol., Immunol. and Infect., 50(1), 62-67.

Biancourt L, Passet V, Nemec A, Dijkshoorn L, Brisse S (2010) The Population Structure of Acinetobacter baumannii: Expanding Multiresistant Clones from an Ancestral Susceptible Genetic Pool. PLoS ONE 5(4): e10034. doi:10.1371/journal.pone.0010034

Heidari, R., &Karbasizade, V. (2014). Frequency and Antimicrobial Susceptibility of Acinetobacter baumannii in Burn infections in Isfahan, Iran. Advan. In Bioresearch, 5(2), 148-152.

Marwan.qader@uod.ac
Wong, D., Nielsen, T. B., Bonomo, R. A., Pantapalangkoor, P., Luna, B., & Spellberg, B. B. (2017). Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. *Clin. Microbiol. Rev.*, 30(1), 409-447.

Sadeghi, P., Khoosravi, A. D., Shahraki, A. H., & Beiranvand, M. (2016). Identification of clinical isolates of *Acinetobacter baumannii* from Iran and study of their heterogeneity. *J. of the Chinese Med. Assoc.*, 79(7), 382-386.

Shahi, S., Vahed, S. Z., Fathi, N., & Sharifi, S. (2018). Polymerase chain reaction (PCR)-based methods: Promising molecular tools in dentistry. *Int. J. of Bio. Macrom.*., 117, 983-992.

McFaddin, J. F. (2000). Biochemical tests for the identification of medical bacteria, 3rd edition, pp. 170–182.

Ghaima, K. K., Saadedin, S. M. K., & Jassim, K. A. (2016). Isolation, molecular identification and antimicrobial susceptibility of *Acinetobacter baumannii* isolated from Baghdad hospitals. *Int. J. of Sci. and Res. Pub.*, 6, (5): 341-356.

Ghasemi E, Ghalavand Z, Goudarzi H, Yeganeh F, Hashemi A, Dabiri H, Mirsamadi ES, Foroumand M. (2016) Clinical and Laboratory Standards Institute (2016) Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement M100-S19. Wayne, USA: CLSI. 26th ed. Pp. 66

Sepideh F., Shahriyar A., Fereshteh S., Soheila A., Mohsen N. and Farzad B. (2020). New putative vaccine candidates against Acinetobacter baumannii using the reverse vaccinology method. Microbial Pathogenesis journal, 143:104114.

Abbott Iain; Cerqueira Gustavo M; Bhuiyan Saruar; Pedersen, P. J., Landersdorfer, C. B., Lee, H. J., Li, J., & Nation, R. L. (2012). ‘Old’antibiotics for emerging multidrug-resistant bacteria. *Current opinion in infectious diseases*, 25(6), 626.

Zarrilli, R., Giannouli, M., Tomason, F., Triassi, Musse, N. H., Al-Mathkhury, H. J. F., & Sabbah, M. A. & Tsakris, A. (2009). Carbapenem resistance in *Acinetobacter baumannii*: the molecular epidemic features of an emerging problem in health care facilities. *The J. of Infect. in Dev. Count.*, 3(05), 335-341.

B. A., & Amyes, S. G. (2014). OXA β-lactamases. *Clin.Microbiol. Rev.*, 27(2), 241-263.

Tilahun, Anteneh Tesfaye, Diriba Muleta, Andualem Bahiru, Zewdu Terefework, Gary Wessel, 2018*“Isolation and Molecular Identification of Lactic Acid Bacteria Using 16s rRNA Genes from Fermented Teff (Eragrostis tef (Zucc.)) Dough”,* International Journal of Food Science, vol. 2018, Article ID 8510620, 7.

Susanna K.P. Lau, Jade L.L. Teng, Chi-Chun Ho, Patrick C.Y. Woo, (2015). Gene Amplification and Sequencing for Bacterial Identification, Editor(s): Andrew Sails, Yi-Wei Tang, Methods in Microbiology, Academic Press, Volume 42, 433-464
isolated from patients and hospitals environment in Baghdad. *Iraqi J. of Sc.*, 54(4), 803-812

Doi, Y., Murray, G. L., & Peleg, A. Y. (2015). *Acinetobacter baumannii*: evolution of antimicrobial resistance—treatment options. In Seminars in respiratory and critical care medicine, 36(1), 85-98.

Balaky, S. T. J., Abdulkhalik, H., Hussen, B. M., Hassan, H., & Mawlood, A. H. (2019). Molecular Identification of *Acinetobacter baumannii* and *Acinetobacter* genome species 13TU Using PCR. *ZANCO J. of Pure and Applied Sci.*, 31(1), 17-22.

Karageorgopoulos, D. E., & Falagas, M. E. (2008). Current control and treatment of multidrug-resistant *Acinetobacter baumannii* infections. *The Lancet Infectious diseases*, 8(12), 751-762.

Shali, A. A. (2012). Identification of Multidrug-Resistant Genes in "*Acinetobacter baumannii*" in Sulaimani City-Kurdistan Regional Government of Iraq. *Asian J. of Med. Sci.*, 4(5), 179-183.

Coskun, U. S. S., Caliskan, E., Cicek, A. C., Turumtay, H., Kanafani, Z., & Kanj, S. (2013). *Acinetobacter* infection: Epidemiology, microbiology, pathogenesis, clinical features, and diagnosis. Wolters Kluwer, 2, 21-33.